Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre …
1. 系统已在2025-11-11 10:06:55对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
M Noureddin, JP Frias, GW Neff, KJ Lucas, C Behling…
The Lancet, 2025
thelancet.com
Background Efruxifermin is a bivalent fibroblast growth factor 21 analogue in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to prospectively assess the safety and efficacy of efruxifermin administration for 96 weeks in individuals with MASH and moderate (stage 2; F2) or severe (stage 3; F3) fibrosis. Methods HARMONY is a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial conducted at 41 academic and community centres in the USA. Adults (aged 18–75 …
